DNAtrix, a Houston, Texas and San Diego, California-based clinical-stage oncolytic immunotherapy company, completed a $20M Series B equity financing.
The round was led by new investor Morningside Ventures with participation from existing investors Mercury Fund, Targeted Technology Fund and others. In conjunction with the funding, for Morningside’s Ms. Reenie McCarthy joined DNAtrix’ Board of Directors.
Led by Frank Tufaro, Ph.D., president and chief executive officer, DNAtrix develops modified viruses for the treatment of cancer. The company intends to use the funds to advance its lead oncolytic virus product, DNX-2401, into late stage clinical trials for glioblastoma.